Legend Biotech (LEGN) Non-Current Debt (2021 - 2025)
Legend Biotech's (LEGN) quarterly Non-Current Debt came in at $319.1 million in Q4 2025, up 5.94% YoY from $301.2 million in Q4 2024, and up 85.6% on a QoQ basis from $171.9 million in Q3 2025.
Legend Biotech (LEGN) Non-Current Debt (2021 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 5 years of Non-Current Debt data on file, last reported at $319.1 million in Q4 2025.
- Quarterly Non-Current Debt rose 5.94% year-over-year to $319.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $319.1 million (up 5.94% YoY) and the FY2025 annual result came in at $319.1 million, up 5.94% from the prior year.
- Non-Current Debt improved to $319.1 million in Q4 2025, from $171.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $319.1 million in Q4 2025 to a low of $17.3 million in Q2 2021.
- A 5-year average of $243.9 million and a median of $278.6 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 116.61% — and 2025, when it sank 42.04%.
- Tracing LEGN's Non-Current Debt over 5 years: stood at $120.5 million in 2021, then surged by 116.61% to $260.9 million in 2022, then rose by 7.82% to $281.3 million in 2023, then climbed by 7.06% to $301.2 million in 2024, then climbed by 5.94% to $319.1 million in 2025.
- The last three Non-Current Debt figures came in at $319.1 million (Q4 2025), $171.9 million (Q3 2025), and $310.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 319.10 Mn |
| Sep 30, 2025 | 171.93 Mn |
| Jun 30, 2025 | 310.26 Mn |
| Mar 31, 2025 | 305.75 Mn |
| Dec 31, 2024 | 301.20 Mn |
| Sep 30, 2024 | 296.62 Mn |
| Jun 30, 2024 | 291.56 Mn |
| Mar 31, 2024 | 286.40 Mn |
| Dec 31, 2023 | 281.33 Mn |
| Sep 30, 2023 | 275.91 Mn |
| Jun 30, 2023 | 270.61 Mn |
| Mar 31, 2023 | 265.86 Mn |
| Dec 31, 2022 | 260.93 Mn |
| Mar 31, 2022 | 126.71 Mn |
| Dec 31, 2021 | 120.46 Mn |
| Jun 30, 2021 | 17.31 Mn |